BCAX

Bicara Therapeutics Inc. (BCAX)
Healthcare • Biotechnology • $23.17 • MCap: 1,533,226,880 🌐
https://www.bicara.com • Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Buy Decision Core
Total Score
35
Business Quality
1
Financial Strength
10
Growth Outlook
1
Momentum
5
Price Action
Current
23.17
52W High
30.40
52W Low
10.44
Above 50DMA
26.44 (-12.35%)
Above 200DMA
21.01 (10.28%)
Relative Strength
Relative Strength
0.34
RS 3M
0.16
RS 6M
0.25
RS 9M
0.28
RS 12M
0.86
Fundamentals
Revenue Growth
0%
Earnings Growth
0%
ROE
-0.41%
ROA
-0.26%
Valuation
PE (Fwd)
-6.74
PEG
0
P/B
3.26
Upside
44.58%
Risk
Beta
0
Short %
0.22
Risk Score
7.00
Analyst
Rating
buy
Target
33.50
Beta
0
Analysts
0
Total Score
35
Upside
44.58%
Relative Strength
0.34
Beta
0
Why Buy?
  • PEG Ratio below 1 (attractive valuation)
  • Trading above 200 DMA
  • Analyst upside exceeds 15%
Key Risks
  • Negative ROE
Score Breakdown
Business
1
Financial
10
Growth
1
Valuation
11
Risk
3
Momentum
5
Technical
52W High: 30.40
52W Low: 10.44
Above 50DMA: -12.35%
Above 200DMA: 10.28%
Valuation
Forward PE: -6.74
PEG: 0
P/B: 3.26
Upside: 44.58%
Risk
Beta: 0
Short Float: 0.22%
ROE: -0.41%
ROA: -0.26%